Bioreactor Virus Production Using Matrix Carriers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for virus production from adherent cells are complex, costly, and yield low quantities due to the need for multiple purification steps and the difficulty in scaling up processes, especially for viruses that do not replicate well in suspension-cultured cells.
Innovation Solution
A method involving the use of bioreactors with a biocompatible matrix for anchorage-dependent cells, where the virus is released from lysed cells and purified using a simplified process of ultrafiltration or diafiltration, or both, allowing for high-yield virus production in a single or two steps, enabling scalable and cost-effective manufacturing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adherent cells are cultured in roller bottles for virus production, then virus replication is effective, but the process becomes difficult and expensive to scale
Solution Approach 1:
The patent transitions from traditional 2D roller bottle culture to a 3D bioreactor system with suspended matrix carriers. Cells grow on the surface of porous matrix beads in a suspended state within the bioreactor, enabling scalable virus production while maintaining adherent cell culture conditions. This dimensional change allows for large-scale production without the limitations of roller bottle configurations.
2Manufacturing precision
If multiple purification steps are used to purify virus from host cell components, then purification completeness is improved, but the process complexity and cost increase
Solution Approach 1:
The patent extracts and removes host cell components during the cell lysis process itself, rather than requiring separate purification steps. By lysing adherent cells grown on matrix carriers directly in the bioreactor, host cell debris remains associated with the matrix while virus particles are released into the culture medium, naturally separating the virus from most cellular components in a single operation.
Solution Approach 2:
The culture medium serves multiple functions: it supports cell growth during the adherent phase, becomes the vehicle for virus release during lysis, and serves as the initial purification medium. This multi-functional use of the same medium eliminates the need for additional purification solvents or complex purification apparatus.
3Productivity
If suspension culture conditions are used, then large volume culture in single bioreactor is achieved, but virus replication efficiency decreases
Solution Approach 1:
The patent introduces porous matrix carriers as an intermediary between suspension culture and adherent cell requirements. The matrix beads provide attachment surfaces for virus-replicating adherent cells while being suspended in large-volume bioreactor culture. This intermediary structure enables both large-scale suspension culture conditions and effective virus replication in adherent cells simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables high-yield virus production in a single day, with recovery rates exceeding 50%, often reaching 95% or more, and can be applied to various viruses, including enveloped types, by retaining cells and debris on the matrix during lysis, simplifying the purification process and reducing operational complexity.
Implementation Method 1
the density of the matrix is such that the cells remain attached under conditions in which cells are lysed and treated to release the virus
Implementation Method 2
purifying the released virus by a simplified, cost-effective single step process of ultrafiltration or diafiltration
Implementation Method 3
purifying the released virus by a simplified, cost-effective single step process of ultrafiltration or diafiltration
Data Source
AI summary
Methods for producing viruses from adherent cells are provided. The methods include releasing virus from adherent host cells grown in a bioreactor, and purifying released virus by ultrafiltration and/or diafiltration. The methods can be used to manufacture viruses, including for clinical use, at reduced cost relative to conventional virus manufacturing methods.